Rational Advisors LLC Biomarin Pharmaceutical Inc Transaction History

Rational Advisors LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 05, 2021	SELL	$72.61 - $90.2 $13,723 - $17,047	-189 Closed	0 $0
Q3 2020 Nov 12, 2020	BUY	$71.87 - $131.03 $11,571 - $21,095	161 Added 575.0%	189 $14,000
Q2 2020 Aug 10, 2020	BUY	$79.55 - $124.22 $2,227 - $3,478	28 New	28 $3,000
Q1 2020 May 12, 2020	SELL	$71.37 - $96.85 $4,496 - $6,101	-63 Closed	0 $0
Q4 2019 Feb 06, 2020	SELL	$64.27 - $86.37 $9,254 - $12,437	-144 Reduced 69.57%	63 $5,000

Q3 2019 Nov 06, 2019	BUY	$67.4 - $85.11 $1,415 - $1,787	21 Added 11.29%	207 $14,000
Q2 2019 Aug 08, 2019	SELL	$80.35 - $93.9 $8,999 - $10,516	-112 Reduced 37.58%	186 $16,000
Q1 2019 May 08, 2019	BUY	$84.2 - $98.62 $24,333 - $28,501	289 Added 3211.11%	298 $26,000
Q4 2018 Feb 07, 2019	SELL	$80.14 - $106.07 $18,432 - $24,396	-230 Reduced 96.23%	9 $1,000
Q3 2018 Nov 08, 2018	BUY	$93.92 - $105.72 $22,071 - $24,844	235 Added 5875.0%	239 $23,000
Q2 2018 Aug 07, 2018	BUY	$76.01 - $99.03 $304 - $396	4 New	4 $0

623

181M

1.73M

1.73M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $15.4B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Rational Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Rational Advisors LLC with notifications on news.